文献速递肥胖与代谢综合征糖尿病

小鼠肝脏Acat2过表达促进全身胆固醇代谢与脂肪组织脂质代谢

Hepatic Acat2 overexpression promotes systemic cholesterol metabolism and adipose lipid metabolism in mice.
PubMed 文献 · Diabetologia · 2022-11-15

研究用AAV9在小鼠肝脏过表达Acat2,观察其对胆固醇和能量代谢的影响。结果显示肝脏Acat2过表达降低体重和总脂肪量、提高代谢率、改善糖耐量并降低血清胆固醇,还改变胆汁酸池和白色脂肪细胞大小。作者认为肝脏腺病毒介导的Acat2过表达可能是治疗肥胖和高胆固醇血症的潜在工具。

要点

  • 肝脏Acat2过表达降低小鼠体重和总脂肪量,提高代谢率。
  • 肝脏Acat2过表达改善糖耐量并降低血清胆固醇水平。
  • 肝脏Acat2过表达改变肝脏胆汁酸池及白色脂肪组织脂质代谢。

核心结论

  • 研究确认ACAT2在胆固醇代谢和全身能量消耗中具有重要作用,并揭示肝脏Acat2过表达带来的代谢获益。
  • 作者认为肝脏腺病毒介导的Acat2过表达可能是治疗肥胖和高胆固醇血症的潜在工具。

研究设计与样本

  • 研究构建肝靶向腺相关病毒9(AAV9)以实现小鼠肝脏Acat2过表达。
  • 小鼠经尾静脉注射AAV9,在正常饮食或高脂饮食下进行形态学、生理学(体成分、间接测热、跑台、葡萄糖耐量试验、血液生化、心脏超声和心电图)、组织化学、基因表达和代谢组学分析。

主要发现

  • 肝脏Acat2过表达降低小鼠体重和总脂肪量,提高代谢率,改善糖耐量并降低血清胆固醇水平。
  • Acat2过表达抑制脂肪酸、葡萄糖和酮体代谢途径,但促进胆固醇代谢并改变肝脏胆汁酸池和组成。
  • 肝脏Acat2过表达减小白色脂肪细胞体积并促进白色脂肪组织脂质代谢。
  • 肝脏Acat2过表达保护小鼠免受高脂饮食诱导的体重增加和代谢缺陷。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Acetyl coenzyme A acetyltransferase (ACAT), also known as acetoacetyl-CoA thiolase, catalyses the formation of acetoacetyl-CoA from acetyl-CoA and forms part of the isoprenoid biosynthesis pathway. Thus, ACAT plays a central role in cholesterol metabolism in a variety of cells. Here, we aimed to assess the effect of hepatic Acat2 overexpression on cholesterol metabolism and systemic energy metabolism. METHODS: We generated liver-targeted adeno-associated virus 9 (AAV9) to achieve hepatic Acat2 overexpression in mice. Mice were injected with AAV9 through the tail vein and subjected to morphological, physiological (body composition, indirect calorimetry, treadmill, GTT, blood biochemistry, cardiac ultrasonography and ECG), histochemical, gene expression and metabolomic analysis under normal diet or feeding with high-fat diet to investigate the role of ACAT2 in the liver. RESULTS: Hepatic Acat2 overexpression reduced body weight and total fat mass, elevated the metabolic rate, improved glucose tolerance and lowered the serum cholesterol level of mice. In addition, the overexpression of Acat2 inhibited fatty acid, glucose and ketone metabolic pathways but promoted cholesterol metabolism and changed the bile acid pool and composition of the liver. Hepatic Acat2 overexpression also decreased the size of white adipocytes and promoted lipid metabolism in white adipose tissue. Furthermore, hepatic Acat2 overexpression protected mice from high-fat-diet-induced weight gain and metabolic defects CONCLUSIONS/INTERPRETATION: Our study identifies an essential role for ACAT2 in cholesterol metabolism and systemic energy expenditure and provides key insights into the metabolic benefits of hepatic Acat2 overexpression. Thus, adenoviral Acat2 overexpression in the liver may be a potential therapeutic tool in the treatment of obesity and hypercholesterolaemia.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Ma Z, Huang Z, Zhang C, et al. Hepatic Acat2 overexpression promotes systemic cholesterol metabolism and adipose lipid metabolism in mice. Diabetologia. 2022. PMID: 36378328. doi:10.1007/s00125-022-05829-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。